Ionis Pharmaceuticals Exceeds Earnings and Revenue Estimates, Provides FY26 Outlook
Ionis Pharmaceuticals (IONS) reported Q1 GAAP EPS of -$0.56, beating estimates by $0.35, and revenue of $246 million, surpassing expectations by $49.99 million. The company also provided its FY26 outlook and reported $1.9 billion in cash and short-term investments as of March 31, 2026.
Tickers: $IONS
Topics: cash reserves earnings financial results GAAP EPS revenue